

Attorney Docket No.: 5515.214-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Knudsen et al.

Serial No.: 09/886,311

Group Art Unit: 1653

Filed: June 21, 2001

Examiner: A. Mohamed

For: Extendin Derivatives (As Amended)

OFFICIAL

**CERTIFICATE OF FACSIMILE TRANSMISSION**

**RECEIVED  
CENTRAL FAX CENTER**

SEP 11 2003

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Request Transfer of Computer Readable Sequence Listing From Parent Case
2. Paper Copy of Sequence Listing from parent application no. 09/312,177 filed May 14, 1999, (2 pages)

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner A. Mohamed at fax number (703) 872-9306 .

Respectfully submitted,

Date: September 11, 2003

*Rashida Haji*

Rashida Haji  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609)987-5800

Attorney Docket No.: 5515.214-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Knudsen et al.

Serial No.: 09/886,311

Group Art Unit: 1653

Filed: June 21, 2001

Examiner: A. Mohamed

For: Extending Derivatives (As Amended)

**REQUEST TRANSFER OF COMPUTER READABLE  
SEQUENCE LISTING FROM PARENT CASE**

Mail Stop Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


Applicants enclose herewith the Sequence Listing for the above-captioned application. The computer-readable form in this application is identical with that filed in Application Serial No. 09/312,177 filed May 14, 1999. In accordance with 37 CFR 1.821(e), please use the [last filed] computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application.

Attorney Docket No.: 5515,214-US

The content of the attached paper entitled "SEQUENCE LISTING" and of the diskette filed in the parent application is the same. Furthermore, the information contained in the attached "SEQUENCE LISTING" and the ASCII-encoded file is identical to the information in the specification as originally filed. No new matter is added.

Respectfully submitted,

Date: September 11, 2003

  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

23650

PATENT TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTER

SEP 11 2003

OFFICIAL

1

## SEQUENCE LISTING

<110> Knudsen, Liselotte B.  
Huusfeldt, Per  
Nielsen, Per  
Madsen, Kjeld

<120> GLP-1 Derivatives II

<130> 5515.204-US

<140> 09/312,177

<141> 1999-05-14

<150> 0274

<151> 1998-02-27

<150> 60/084,357

<151> 1998-05-05

<160> 3

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 31

<212> PRT

<213> Artificial Sequence

<220> Xaa at position 31 is any amino acid

<223> Variation

<400> 1

His	Gly	Glu	Gly	Thr	Phe	Thr	Ser	Asp	Leu	Ser	Lys	Gln	Met	Glu	Glu
1				5				10					15		
Glu	Ala	Val	Arg	Leu	Phe	Ile	Glu	Trp	Leu	Lys	Asn	Gly	Gly	Xaa	
			20					25					30		

<210> 2

<211> 40

<212> PRT

<213> Artificial Sequence

<220> Xaa at positions 2 and 3 is any amino acid

<223> Variation

<400> 2

His	Xaa	Xaa	Gly	Thr	Phe	Ile	Thr	Ser	Asp	Leu	Ser	Lys	Gln	Met	Glu
1				5				10					15		
Glu	Glu	Ala	Val	Arg	Leu	Phe	Ile	Glu	Trp	Leu	Lys	Asn	Gly	Gly	Pro
			20					25					30		
Ser	Ser	Gly	Ala	Pro	Pro	Pro	Ser								
		35					40								

5515.204-US

2

<210> 3  
<211> 31  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Variation

<400> 3  
Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu  
1 5 10 15  
Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser  
20 25 30